Novo Nordisk A/S (NVO)
41.65
+1.00
(+2.46%)
USD |
NYSE |
Nov 13, 16:00
41.48
-0.17
(-0.41%)
After-Hours: 18:16
Novo Nordisk EPS Diluted (Quarterly) : 0.5825 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.5825 |
| June 30, 2026 | 0.7362 |
| March 31, 2026 | 1.709 |
| December 31, 2025 | 0.9419 |
| September 30, 2025 | 0.7044 |
| June 30, 2025 | 0.9054 |
| March 31, 2025 | 0.9212 |
| December 31, 2024 | 0.9061 |
| September 30, 2024 | 0.9012 |
| June 30, 2024 | 0.648 |
| March 31, 2024 | 0.8273 |
| December 31, 2023 | 0.7073 |
| September 30, 2023 | 0.7309 |
| June 30, 2023 | 0.6304 |
| March 31, 2023 | 0.6329 |
| December 31, 2022 | 0.4121 |
| September 30, 2022 | 0.4297 |
| June 30, 2022 | 0.4185 |
| March 31, 2022 | 0.4692 |
| December 31, 2021 | 0.3654 |
| September 30, 2021 | 0.4181 |
| June 30, 2021 | 0.4261 |
| March 31, 2021 | 0.4414 |
| December 31, 2020 | 0.321 |
| September 30, 2020 | 0.3462 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.3345 |
| March 31, 2020 | 0.3725 |
| December 31, 2019 | 0.2733 |
| September 30, 2019 | 0.32 |
| June 30, 2019 | 0.3029 |
| March 31, 2019 | 0.3318 |
| December 31, 2018 | 0.27 |
| September 30, 2018 | 0.2914 |
| June 30, 2018 | 0.3401 |
| March 31, 2018 | 0.3631 |
| December 31, 2017 | 0.2658 |
| September 30, 2017 | 0.3127 |
| June 30, 2017 | 0.2969 |
| March 31, 2017 | 0.291 |
| December 31, 2016 | 0.2506 |
| September 30, 2016 | 0.2902 |
| June 30, 2016 | 0.2975 |
| March 31, 2016 | 0.2741 |
| December 31, 2015 | 0.2369 |
| September 30, 2015 | 0.2428 |
| June 30, 2015 | 0.2394 |
| March 31, 2015 | 0.286 |
| December 31, 2014 | 0.2098 |
| September 30, 2014 | 0.2205 |
| June 30, 2014 | 0.2435 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AstraZeneca PLC | 0.9849 |
| GSK Plc | 1.018 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.221 |
| Merck & Co., Inc. | 2.044 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 2.576B |
| Revenue (Quarterly) | 12.19B |
| Total Expenses (Quarterly) | 9.612B |
| Enterprise Value | 149.40B |
| Gross Profit Margin (Quarterly) | 82.10% |
| Profit Margin (Quarterly) | 21.14% |
| Earnings Yield | 9.53% |
| Operating Earnings Yield | 13.57% |
| Normalized Earnings Yield | 10.56 |